Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study

Harry J. M. Groen*, Erik H. F. M. van der Heijden, Theo J. Klinkenberg, Bonne Biesma, Joachim Aerts, Ad Verhagen, Corinne Kloosterziel, Remge Pieterman, Ben van den Borne, Hans J. M. Smit, Otto Hoekstra, Frans M. N. H. Schramel, Vincent van der Noort, Harm van Tinteren, Egbert F. Smit, Anne-Marie C. Dingemans, NVALT Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)372-377
Number of pages6
JournalBritish Journal of Cancer
Volume121
Issue number5
DOIs
Publication statusPublished - 27 Aug 2019

Keywords

  • MOLECULAR-WEIGHT HEPARIN
  • POSITRON-EMISSION-TOMOGRAPHY
  • SURVIVAL
  • MULTICENTER
  • THERAPY
  • SCAN
  • PET

Cite this

Groen, H. J. M., van der Heijden, E. H. F. M., Klinkenberg, T. J., Biesma, B., Aerts, J., Verhagen, A., Kloosterziel, C., Pieterman, R., van den Borne, B., Smit, H. J. M., Hoekstra, O., Schramel, F. M. N. H., van der Noort, V., van Tinteren, H., Smit, E. F., Dingemans, A-M. C., & NVALT Study Grp (2019). Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. British Journal of Cancer, 121(5), 372-377. https://doi.org/10.1038/s41416-019-0533-3